Analysed CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) News Sources
Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
07-04-2026
yahoo.com
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%
11-03-2026
yahoo.com
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
09-03-2026
yahoo.com
Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead
26-02-2026
marketbeat.com
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
12-02-2026
yahoo.com
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
05-01-2026
yahoo.com
While hedge funds own 24% of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), retail investors are its largest shareholders with 46% ownership
27-12-2025
yahoo.com
What is the current price of CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ)?
The current price of CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) is $9.8.
CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) absolute price change since previous trading day?
The absolute price change of CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) since the previous trading day is $-0.52.
CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) percentage price change since previous trading day?
The percentage price change of CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) since the previous trading day is -5.0388%.
What is the most recent average sentiment score for CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ)?
The most recent average sentiment score for CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) is 62 out of 100.
What is the most recent average sentiment for CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ)?
The most recent sentiment for CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) is .
SEC-8K** Filing Available For CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.